Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The impact of cotrimoxazole (CTX) on growth and/or anemia was investigated in 541 human immunodeficiency virus-infected, antiretroviral therapy-naive Zambian children enrolled in the Children with HIV Antibiotic Prophylaxis trial. Compared with children randomized to receive placebo, children randomized to receive CTX had slower decreases in weight-for-age (P=.04) and height-for-age (P=.01), and greater increase in hemoglobin level (P=.01). These findings argue for expanded early CTX use.

Original publication

DOI

10.1093/cid/cir029

Type

Journal article

Journal

Clin Infect Dis

Publication Date

01/04/2011

Volume

52

Pages

953 - 956

Keywords

Adolescent, Anemia, Antimalarials, Body Height, Body Weight, Chemoprevention, Child, Child Development, Child, Preschool, Female, HIV Infections, Humans, Infant, Malaria, Male, Placebos, Trimethoprim, Sulfamethoxazole Drug Combination, Zambia